OS Therapies' OST-HER2: A Beacon of Hope in the Fight Against Osteosarcoma

In the relentless pursuit of innovative cancer treatments, OS Therapies has emerged as a beacon of hope with its groundbreaking immunotherapy, OST-HER2. The company's latest milestone—being featured in the upcoming documentary "Shelter Me: The Cancer Pioneers"—marks a significant step in raising awareness and garnering support for its pioneering work in osteosarcoma treatment. The documentary, set to premiere at AMC Century City in Los Angeles on April 3, 2025, and available for streaming on PBS platforms in May, delves into the fascinating world of canine comparative oncology, highlighting the 96% genetic similarity between human and canine osteosarcoma. This genetic overlap underscores the importance of comparative oncology research, a field that OS Therapies is at the forefront of.



The documentary not only sheds light on the scientific advancements but also evokes an emotional response from viewers, making them more likely to support and invest in OS Therapies' mission. By featuring leading scientists from prestigious institutions such as the National Cancer Institute, University of Pennsylvania, University of Illinois, University of Wisconsin, and Colorado State University, the documentary enhances the credibility of OS Therapies and its immunotherapy treatment, OST-HER2.

OST-HER2 is an experimental immunotherapy for osteosarcoma that uses a bioengineered form of Listeria monocytogenes bacteria targeting HER2-expressing cancer cells. The treatment has shown promising results in clinical trials, demonstrating a statistically significant benefit in the 12-month event-free survival (EFS) primary endpoint. This success has attracted the attention of potential investors, who see the company's stock as a promising investment opportunity. Analysts have given OS Therapies a "Strong Buy" rating, with an average target price of $17.50, representing a 941.67% increase from the current stock price of $1.68.

The financial implications of the Biologics Licensing Application (BLA) for OST-HER2, if approved by the US FDA in 2025, could be profound. The company would become eligible to receive a Priority Review Voucher, which it could then sell. This voucher allows the holder to receive priority review for a subsequent marketing application, which can be a valuable asset for pharmaceutical companies. The sale of this voucher could provide a substantial financial windfall for OS Therapies.



Additionally, the approval of OST-HER2 would validate the company's research and development efforts, potentially leading to increased investor confidence and a higher stock price. The financial forecast for OS Therapies also suggests significant growth. The company's revenue is projected to increase from $139,740 in 2024 to $37.4 million in 2025, a staggering 26,664% increase. This dramatic rise in revenue would likely be driven by the approval and commercialization of OST-HER2. Similarly, the company's earnings per share (EPS) are expected to turn positive, moving from -$1.09 in 2024 to $0.72 in 2025. This turnaround in profitability would further bolster investor confidence and potentially drive up the company's market valuation.

In summary, the feature of OST-HER2 in the documentary "Shelter Me: The Cancer Pioneers" and the potential approval of the BLA for OST-HER2 by the US FDA in 2025 could have profound implications for OS Therapies. The documentary serves as a platform to showcase the company's groundbreaking work and generate interest in its stock, while the approval of OST-HER2 could lead to significant financial benefits, including the potential sale of a Priority Review Voucher, increased investor confidence, a higher stock price, and substantial revenue and earnings growth. These factors combined could lead to a substantial increase in the company's market valuation, making OS Therapies a promising investment opportunity in the fight against osteosarcoma.